SAB Biotherapeutics, Inc. (SABS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Samuel J. Reich	CEO & Director	846,462	1975
Christoph Bausch	Executive Vice President & Chief Operating Officer	609,000	1971
Lucy To	Executive Vice President & Chief Financial Officer	684,034	1986
Eddie Joe Sullivan	Co-Founder, President & Director	746,500	1967
Alexandra Kropotova	Executive Vice President & Chief Medical Officer	832,249	1973
Carlos N. Carillo	Senior Vice President of Regulatory Affairs	0	N/A
Angie Parizek	Senior Vice President of Clinical Operations	0	N/A
Cristi Barnett	Vice President of Investor Relations & Corporate Communications	0	N/A
Hua Wu	Senior Vice President of Product Development	0	N/A
Catherine DeRose	Vice President of Human Resources	0	N/A

Name

Title

Pay

Year Born

Samuel J. Reich

CEO & Director

846,462

1975

Christoph Bausch

Executive Vice President & Chief Operating Officer

609,000

1971

Lucy To

Executive Vice President & Chief Financial Officer

684,034

1986

Eddie Joe Sullivan

Co-Founder, President & Director

746,500

1967

Alexandra Kropotova

Executive Vice President & Chief Medical Officer

832,249

1973

Carlos N. Carillo

Senior Vice President of Regulatory Affairs

N/A

Angie Parizek

Senior Vice President of Clinical Operations

N/A

Cristi Barnett

Vice President of Investor Relations & Corporate Communications

N/A

Hua Wu

Senior Vice President of Product Development

N/A

Catherine DeRose

Vice President of Human Resources

N/A

Description

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies. The company leverages sophisticated genetic engineering and antibody research to cultivate specialized transchromosomic bovine herds. These unique animals are engineered to generate fully human antibodies, which are then directed against a variety of specific ailments. This broad scope includes infectious diseases such as COVID-19 and influenza, various immune and autoimmune conditions like type 1 diabetes, and potential applications in organ transplantation and cancer treatment. Central to their strategy is the proprietary DiversitAb immunotherapy platform, which yields wholly human polyclonal antibodies, thereby circumventing the need for human donors. Key assets in their clinical pipeline feature SAB-185, a fully human polyclonal antibody therapeutic currently undergoing Phase III trials for COVID-19, and SAB-176, another fully human polyclonal antibody in development for the prevention or treatment of severe influenza. Additionally, their preclinical portfolio contains SAB-142, intended for autoimmune disorders such as type 1 diabetes and for managing organ transplant induction/rejection. Established in 2014, SAB Biotherapeutics is based in Sioux Falls, South Dakota.